[The Wall Street Journal] France Will use Taxes to Pressure Drug Makers on Hep C Prices
Sep 30, 2014
In an effort to blunt the high price of hepatitis C treatments… Read More
© 2024 CSRXP- All Rights Reserved
Updates
[The Washington Examiner] America’s other drug war
Sep 22, 2014
Winston Churchill famously described an appeaser as "one who feeds a crocodile, hoping it will eat him last." Today, in a very different context, his remark captures the plight of the American pharmaceutical industry. Read More
[The Washington Post] The new $84,000 hepatitis C treatment is losing momentum, for now
Sep 18, 2014
After recording the best launch of any drug in history, it looks like the pace is starting to slow down for Gilead Sciences' Sovaldi — the new $84,000 hepatitis C cure that's sparking a new focus on specialty drug costs. Read More
[Reuters] Study shows downward trend in Sovaldi utilization
Sep 17, 2014
Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. Read More
Gilead–The Predictable Path or the Road Less Traveled?
Sep 17, 2014
Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families. Read More
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’
Sep 17, 2014
AIDS Healthcare Foundation (AHF), the largest global AIDS organization and an outspoken advocate against runaway drug pricing for lifesaving HIV/AIDS and other medications, has teamed with the National Coalition on Health Care and others on the ‘Campaign for Sustainable Rx Pricing’ to spotlight what the group characterizes as “unsustainable and abusive” prices for some medicines. Read More
[The New York Times] Gilead, Maker of Hepatitis C Drug, Strikes Deal on Generics for Poor Countries
Sep 15, 2014
Gilead announced that it had struck agreements with seven Indian generic drug makers to sell lower-cost versions of its $1,000-a-pill Hepatitis C drug in poorer countries. The deals are intended to provide greater access to the medicine Sovaldi for most of the nearly 180 million infected worldwide with Hepatitis C who do not live in rich countries. Some 350,000 people die every year of Hepatitis C infections, most of them in middle- and low-income nations. Read More
[The Street] Retrophin Assailed for ‘Exorbitant’ Price Hike
Sep 10, 2014
Runaway drug pricing has become a recent hot topic, witnessed best by the media and political bashing of Gilead Sciences (GILD_) for the $1,000-per-day cost of its hepatitis C pill Sovaldi. Read More
[The Boston Globe] New Genzyme drug comes at a high price
Sep 9, 2014
There are a lot of innovative therapies with encouraging prospects and eye-popping price tags in the news lately. All of them pose hard questions about the big commercial risks drug companies must take and the enormous pricing power of medicines that can help suffering patients. Read More
[Des Moines Register] State paying for pricey pill to treat Hepatitis C
Sep 8, 2014
The state of Iowa has started paying $1,000 per pill for a new drug targeting hepatitis C, but officials don't plan to buy the medication for every person who carries the virus and qualifies for public health care. Read More
[Bloomberg] Gilead Close to Sending $84,000 Drug to Poor Countries
Sep 5, 2014
Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India,Indonesia, and Pakistan. Read More
[WSJ] How Much? Some Generic Drug Prices Are Skyrocketing: Analysis
Aug 14, 2014
A new analysis finds that half of all generic drugs sold through retailers became more expensive over the past 12 months. In fact, the prices paid by pharmacies more than doubled for one out of 11 generics. Read More